You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection
  1. Muhammad Baraa Hammami1,
  2. Reem Aboushaar2 and
  3. Eyad Alsabbagh3
  1. 1 Department of Internal Medicine, Florida Atlantic University, Boca Raton, Florida, USA
  2. 2 Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA
  3. 3 Division of Gastroenterology and Hepatology, Saint Louis University, Saint Louis, Missouri, USA
  1. Correspondence to Dr Muhammad Baraa Hammami, mhammami{at}health.fau.edu

Abstract

The combination of glecaprevir and pibrentasvir was recently approved for chronic hepatitis C virus (HCV) infection with recommended treatment duration of 8–12 weeks depending on previous treatments, viral genotype and cirrhosis status. Although liver injury was reported with other protease inhibitors in the presence of cirrhosis or hepatitis B virus (HBV) co-infection, glecaprevir/pibrentasvir treatment is not known to cause liver injury. We report a patient with chronic HCV infection who despite the absence of cirrhosis and HBV co-infection developed acute liver injury that completely resolved after glecaprevir/pibrentasvir withdrawal. Interestingly, sustained HCV virologic response was achieved after only 3 weeks of glecaprevir/pibrentasvir treatment.

  • drugs: gastrointestinal system
  • hepatitis C
  • gastrointestinal system
  • hepatitis and other GI infections

https://doi.org/10.1136/bcr-2018-226622

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors MBH wrote the manuscript. RA participated in literature review. EA edited the manuscript. Article guarantor: EA.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.